Skip to main content
CORDIS - Forschungsergebnisse der EU
CORDIS

DNA replication at the heart of cell fate decisions and cancer development

Projektbeschreibung

Die Rolle der DNS-Replikation beim Zellschicksal

Die Genauigkeit einer Genomduplizierung mittels DNS-Replikation kann durch verschiedene Stressfaktoren beeinträchtigt werden – mit gravierenden Folgen für die Genomintegrität und das Zellschicksal. Das im Rahmen der Marie-Skłodowska-Curie-Maßnahmen finanzierte Projekt RepliFate zielt auf die Untersuchung der Mechanismen ab, durch welche die DNS-Replikation das Zellschicksal beeinflusst und sogar Krebs und andere Erkrankungen verursachen kann. Das Projekt wird Ausbildungsmöglichkeiten für europäische Forschende anbieten und grundlegendes Wissen zum Prozess der malignen Transformation hervorbringen. Durch die Ermittlung der zentralen Faktoren der DNS-Replikation wird es einen Beitrag leisten, der die zukünftige Entwicklung von innovativen Krebsbehandlungen voranbringen wird.

Ziel

RepliFate is doctoral network designed to train the next generation of European researchers in the field of DNA replication, cell fate and cancer. We have designed an innovative training program that aims at providing interdisciplinary and intersectoral formation for the fellows. We base the network in inclusion, creativity and communication as the base to train the researchers in all aspects of scientific activity.

RepliFate will investigate the mechanisms through which changes in DNA replication influence cell identity, respond to different kinds of stress, and prevent malignant transformation. We will put DNA replication at the center stage as the driver of these processes and not a mere bystander, using recent technological to better understand the role of DNA replication as a determinant of cell fate and cancer. RepliFate links academia with industry and society and will provide new opportunities for innovation in one of the main societal challenges in human health, cancer. The scientific roots of RepliFate are set on the Horizon Europe Mission Cancer objectives Understand and Optimise. We will pave the way for the development of innovative cancer treatments exploring the links between DNA replication and cell fate, the immune response and unscheduled cell proliferation.

RepliFate is composed by 10 European beneficiaries (9 from academia and 1 from industry) along with 2 Swiss associated partners (with their own funding from the Swiss government), 4 companies, 1 news agency and 2 non-profit organizations as associated partners from 8 different countries. Putting the focus on the fellows, we have combined our expertise to create an outstanding training program with the objective to generate leaders in the field with independent and out-of-the-box views to drive the knowledge of basic science to applications that will improve the resilience of the European society by positively impacting on our response to the huge health challenge constituted by Cancer.

Koordinator

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Netto-EU-Beitrag
€ 755 913,60
Adresse
CALLE SERRANO 117
28006 Madrid
Spanien

Auf der Karte ansehen

Region
Comunidad de Madrid Comunidad de Madrid Madrid
Aktivitätstyp
Research Organisations
Links
Gesamtkosten
Keine Daten

Beteiligte (7)

Partner (13)